Skip to main content

Table 4 Clinical validity: known-group comparisons of the Taiwan Chinese EORTC QLQ-C30 and QLQ-CR29

From: Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients

Scale Treatment   ECOG Status Score   Bristol Stool Scale  
Active treatment Follow-up P-value& ECOG = 0 ECOG = 1,2,3 P-value& BSS = 0,1,2,3,4 BSS = 5,6 P-value&
n = 53 n = 55   n = 81 n = 27   n = 55 n = 53  
QLQ-C30 function
 QL2 57.5 70.3 0.005 66.6 54.7 0.018 61.4 66.5 0.279
 PF 83.5 80.3 0.233 87.3 67.3 0.000 81.9 81.8 0.774
 RF 75.5 83.6 0.112 84.0 68.5 0.015 77.5 81.8 0.544
 EF 81.0 80.8 0.783 81.5 78.7 0.384 79.9 81.9 0.821
 CF 81.1 78.3 0.529 81.3 74.7 0.113 77.8 81.7 0.264
 SF 74.5 81.8 0.081 80.4 71.3 0.062 74.1 82.4 0.049
QLQ-C30symptom
 FA 31.7 29.1 0.717 26.4 42.5 0.001 31.1 29.6 0.698
 NV 9.4 7.0 0.570 8.1 8.6 0.958 10.3 6.0 0.064
 PA 18.2 16.1 0.734 15.0 24.1 0.020 18.5 15.7 0.400
 DY 10.9 15.2 0.306 12.5 15.4 0.278 11.1 15.1 0.359
 SL 21.4 27.7 0.321 23.6 26.9 0.836 23.0 26.1 0.512
 AP 21.4 11.5 0.063 13.8 24.7 0.041 21.2 11.3 0.034
 CO 23.3 25.3 0.601 21.1 33.3 0.032 22.2 26.4 0.310
 DI 25.2 21.4 0.881 24.6 20.0 0.637 24.7 21.8 0.476
 FI 15.1 15.1 0.910 15.4 13.3 0.996 17.3 12.8 0.334
QLQ-CR29 function
 BI 86.5 86.8 0.819 86.2 88.9 0.693 87.7 85.6 0.359
 ANX 58.3 67.3 0.061 63.7 60.0 0.490 62.3 63.4 0.948
 WEI 75.6 73.6 0.691 73.4 78.7 0.427 76.5 72.5 0.354
 SEXF 15.6 19.3 0.444 21.5 5.3 0.000 15.3 19.7 0.446
QLQ-CR29 symptom
 UF 22.8 20.4 0.781 17.3 34.0 0.001 22.8 20.3 0.644
 BMS 19.3 4.4 0.000 11.1 14.0 0.661 13.5 9.8 0.744
 SF2 22.2 19.3 0.852 19.9 23.3 0.796 21.7 19.7 0.850
 UI 5.1 7.5 0.971 6.3 5.3 0.842 5.6 7.2 0.750
 DY2 3.2 1.9 0.451 3.0 1.3 0.434 3.7 1.3 0.169
 AP2 13.5 14.5 0.426 14.3 13.3 0.479 11.7 16.3 0.110
 BP 12.0 8.2 0.277 9.3 13.0 0.865 12.2 7.8 0.203
 BF 21.2 19.9 0.980 20.5 20.0 0.612 18.5 22.7 0.213
 DM 31.4 26.4 0.205 28.3 30.7 0.529 27.2 30.7 0.267
 HL 19.2 15.7 0.469 18.6 14.7 0.450 19.5 15.3 0.950
 TA 9.6 12.8 0.596 13.2 5.3 0.133 11.3 11.1 0.916
 FL 21.3 22.2 0.866 20.4 26.7 0.346 17.3 26.5 0.059
 FI2 8.7 12.4 0.390 12.0 6.7 0.204 10.3 10.9 0.901
 SS 9.7 6.7 0.389 6.5 13.3 0.123 8.8 7.5 0.514
 EMB 14.3 13.1 0.616 13.1 16.0 0.516 11.8 15.6 0.514
 STO 11.1 0.0 0.138 3.3 11.1 0.418 0.0 6.7 0.500
 IMP 17.1 25.0 0.100 18.9 23.8 0.894 21.5 19.0 1.000
 DYS 11.9 8.0 0.417 12.6 0.0 0.071 9.3 9.5 0.889
  1. QL2 global health/quality of life, PF physical function, RF role function, EF emotion function, CF cognitive function, SF social function, FA fatigue, NV nausea/vomiting, PA pain, DY dyspnea, SL insomnia, AP appetite loss, CO constipation, DI diarrhea, FI financial difficulty, BI body image, ANX anxiety, WEI weight, SEXF sexual interest, UF urinary frequency, BMS blood and mucus in stool, SF2 stool frequency, UI urinary incontinence, DY2 dysuria, AP2 abdominal pain, BP buttock pain, BF bloating, DM dry mouth, HL hair loss, TA taste, FL flatulence, FI2 faecal incontinence, SS sore skin, EMB embarrassment, STO stoma care problem, IMP importance, DYS dyspareunia
  2. &Wilcoxon rank sum test. P-values in boldface indicate significant between-group difference in quality of life scores
  3. Quality of life scores presented as medium (interquartile range)